Guest guest Posted May 12, 2009 Report Share Posted May 12, 2009 Canopus BioPharma Inc. (OTCPK: CBIA) today announced it has commissioned a team of experts (AN EXPERT IS A DRIP UNDER PRESSURE I SEEM TO REMEMBER!) led by Dr. Akihiro Shimosaka, to assist with its plans for major collaborations to license, manufacture and distribute its H1N1 Swine flu statin antiviral. This team is currently in negotiations with the Office of Disease Control and Emergency Response, the CDC and the SFDA in China with a view to initiating large scale clinical trials and gaining marketing approval on behalf of Canopus BioPharma. http://www.businesswire.com/portal/site/google/?ndmViewId=news_view & newsId=20090512005701 & newsLang=en Comments care of Clare in Tassie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.